- Home
- FF vs MDXH Comparison
FF vs MDXH Comparison
Compare FF & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FF
- MDXH
- Stock Information
- Founded
- FF N/A
- MDXH 2003
- Country
- FF United States
- MDXH Belgium
- Employees
- FF N/A
- MDXH N/A
- Industry
- FF Major Chemicals
- MDXH
- Sector
- FF Industrials
- MDXH
- Exchange
- FF Nasdaq
- MDXH Nasdaq
- Market Cap
- FF 176.1M
- MDXH 203.4M
- IPO Year
- FF N/A
- MDXH 2021
- Fundamental
- Price
- FF $3.16
- MDXH $3.28
- Analyst Decision
- FF
- MDXH Strong Buy
- Analyst Count
- FF 0
- MDXH 3
- Target Price
- FF N/A
- MDXH $7.67
- AVG Volume (30 Days)
- FF 184.1K
- MDXH 333.0K
- Earning Date
- FF 11-10-2025
- MDXH 11-12-2025
- Dividend Yield
- FF 7.64%
- MDXH N/A
- EPS Growth
- FF N/A
- MDXH N/A
- EPS
- FF N/A
- MDXH N/A
- Revenue
- FF $137,409,000.00
- MDXH $103,069,000.00
- Revenue This Year
- FF N/A
- MDXH $24.78
- Revenue Next Year
- FF N/A
- MDXH $21.20
- P/E Ratio
- FF N/A
- MDXH N/A
- Revenue Growth
- FF N/A
- MDXH 21.68
- 52 Week Low
- FF $3.09
- MDXH $1.35
- 52 Week High
- FF $5.78
- MDXH $5.33
- Technical
- Relative Strength Index (RSI)
- FF 29.71
- MDXH 26.74
- Support Level
- FF $3.09
- MDXH $2.75
- Resistance Level
- FF $3.33
- MDXH $4.98
- Average True Range (ATR)
- FF 0.14
- MDXH 0.28
- MACD
- FF -0.07
- MDXH -0.17
- Stochastic Oscillator
- FF 7.47
- MDXH 23.45
About FF FutureFuel Corp. Common shares
FutureFuel Corp makes and sells diversified chemical products, bio-based fuel products, and specialty chemical products. The company is organized into two segments based on product type: biofuels and chemicals. The biofuel segment sells biodiesel and other petroleum products. Its fuels are made from a mix of diesel, vegetable oils, and grease feedstock. The chemicals segment sells products that are used in the production of agricultural chemicals, which include herbicides, coatings, and cleaning products, such as detergents.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.